SEARCH

SEARCH BY CITATION

References

  • 1
    Canadian Cancer Statistics 2011. Public Health Agency of Canada., 2011.
  • 2
    Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can 2003; 24: 91101.
  • 3
    Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 54473.
  • 4
    Sewitch MJ, Fournier C, Ciampi A, et al. Adherence to colorectal cancer screening guidelines in Canada. Biomed Chromatogr Gastroenterol 2007; 7: 39.
  • 5
    Sewitch MJ, Fournier C, Ciampi A, et al. Colorectal cancer screening in Canada: results of a national survey. Chronic Dis Can 2008; 29: 921.
  • 6
    Lau A, Gregor JC. Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario. Can J Gastroenterol 2007; 21: 3717.
  • 7
    Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 1629.
  • 8
    Ritchie SA, Ahiahonu PW, Jayasinghe D, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. Biomed Chromatogr Med 2010; 8: 13.
  • 9
    Ritchie SA, Heath D, Yamazaki Y, et al. Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. Biomed Chroomatogr Gastroenterol 2010; 10: 140.
  • 10
    Ritchie SA, Jayasinghe D, Davies GF, et al. Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res 2011; 30: 59.
  • 11
    Feeley TH, Cooper J, Foels T, et al. Efficacy expectations for colorectal cancer screening in primary care: identifying barriers and facilitators for patients and clinicians. Health Commun 2009; 24: 30415.
  • 12
    Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med 2006; 30: 3139.
  • 13
    McGregor S, Hilsden R, Yang H. Physician barriers to population-based, fecal occult blood test-based colorectal cancer screening programs for average-risk patients. Can J Gastroenterol 2010; 24: 35964.
  • 14
    Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 4228.
  • 15
    Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. New Engl J Med 2001; 345: 55560.
  • 16
    Strul H, Kariv R, Leshno M, et al. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40–80 years. Am J Gastroenterol 2006; 101: 25562.
    Direct Link:
  • 17
    Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G717.
  • 18
    Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol 2007; 23: 4854.
  • 19
    Harpaz N, Polydorides AD. Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 2010; 134: 87695.
  • 20
    Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002; 64: 2743.
  • 21
    Heitman SJ, Ronksley PE, Hilsden RJ, et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 12728.